Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524707 | 1.00 | HSD17B10 (0.43) | HSD17B10HPGDSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL14451329 | 1.00 | HSD17B10 (0.43) | HSD17B10HPGDSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL14451330 | 1.00 | HSD17B10 (0.43) | HSD17B10HPGDSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL5520765 | 0.90 | HSD17B10 (0.44) | HSD17B10HPGDSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL5516274 | 0.81 | SMN1; SMN2 (0.49) | HPGDSMN1; SMN2ALDH1A1L3MBTL1ACACB | |
| SCHEMBL5519303 | 0.81 | SMN1; SMN2 (0.49) | HPGDSMN1; SMN2ALDH1A1L3MBTL1ACACB | |
| SCHEMBL5519107 | 0.81 | ACACB (0.46) | HPGDSMN1; SMN2L3MBTL1ACACBLMNA | |
| SCHEMBL5532649 | 0.81 | ACACB (0.41) | HPGDSMN1; SMN2ALDH1A1L3MBTL1ACACB | |
| SCHEMBL5521109 | 0.80 | ACACB (0.41) | HPGDSMN1; SMN2ALDH1A1L3MBTL1ACACB | |
| SCHEMBL5525322 | 0.80 | ACACB (0.51) | HPGDSMN1; SMN2ALDH1A1L3MBTL1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | HSD17B10 1891/4885HPGD 604/4885SMN1; SMN2 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.